UW Madison researchers have developed a virus-free, CRISPR-Cas mediated method of generating T cells that target senescent cells. These modified T cells could be used to treat Alzheimer’s Disease an...
Learn More

UW-Madison researchers have identified novel ACE2 mutants having enhanced activity and/or specificity in hydrolyzing angiotensin II. ACE2 (angiotensin converting enzyme 2) is a key metalloprotease of ...
Learn More

UW-Madison researchers have developed a novel fusion protein for inducing Breg cell formation and a method for transforming any human B cell into an IL10-competent, functional Breg cell ex vivo at sca...
Learn More

A composition for the treatment of bladder fibrosis in a patient in need that includes a miR-29 mimic is disclosed. The miR-29 mimic may include a working RNA strand with the nucleotide sequence UAGCA...
Learn More

Regulatory elements that drive Schwann cell-specific gene expression, nucleic acid vectors, virus particles, and therapeutic compositions incorporating these constructs; and methods of using these var...
Learn More

Friedreich’s Ataxia (FRDA) is a neurodegenerative disorder without treatments to halt or reverse disease progression, affecting roughly 9,000 Americans. FRDA is caused by triplet expansion in the fi...
Learn More

Pompe disease is a rare autosomal recessive genetic disease (mutations from both parent carriers have to be inherited by the offspring to see symptoms) that typically affects children during developme...
Learn More

Friedreich’s ataxia (also referred to as FA or FRDA) is a rare but fatal autosomal recessive neurodegenerative disease. With an estimated incidence of 1 in every 40,000 people, it causes progressive...
Learn More